Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML

Aptevo Therapeutics Inc.

Of 14 evaluable TP53-mutated frontline AML patients, 13 (93%) achieved clinical benefit; 11 (79%) achieved CR/CRi, including 9 CRs.
79% CR/CRi compares favorably to published 41% composite remission rate for venetoclax plus azacitidine in this population.
RAINIER dose optimization trial expected to complete by year-end 2026; regulatory interaction planned for 1H27.
Data include two patients from previously completed dose expansion trial; mipletamig combined with venetoclax and azacitidine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.